TipRanks
Advertisement
Advertisement
Nuvation Bio Targets Post‑Vorasidenib Glioma With New Safusidenib Trial
PremiumCompany AnnouncementsNuvation Bio Targets Post‑Vorasidenib Glioma With New Safusidenib Trial
1M ago
Nuvation Bio price target raised to $14 from $12 at B. Riley
Premium
The Fly
Nuvation Bio price target raised to $14 from $12 at B. Riley
1M ago
Nuvation Bio price target raised to $20 from $19 at RBC Capital
Premium
The Fly
Nuvation Bio price target raised to $20 from $19 at RBC Capital
1M ago
Boris Peaker Reaffirms Buy on Nuvation Bio, Citing Strong Safusidenib Data in IDH1-Mutant Glioma and Expanding Global Commercial Strategy
PremiumRatingsBoris Peaker Reaffirms Buy on Nuvation Bio, Citing Strong Safusidenib Data in IDH1-Mutant Glioma and Expanding Global Commercial Strategy
2M ago
RBC looks for Nuvation shares to appreciate as safusidenib data builds
Premium
The Fly
RBC looks for Nuvation shares to appreciate as safusidenib data builds
2M ago
Nuvation Bio announces data from the Phase 2 J201 study
Premium
The Fly
Nuvation Bio announces data from the Phase 2 J201 study
2M ago
Nuvation Bio Issues Convertible Notes, Retires Secured Debt
PremiumCompany AnnouncementsNuvation Bio Issues Convertible Notes, Retires Secured Debt
3M ago
Nuvation Bio announces MHRA in UK approves MAA for taletrectinib
Premium
The Fly
Nuvation Bio announces MHRA in UK approves MAA for taletrectinib
3M ago
Nuvation Bio prices upsized offering of $250M of convertible senior notes
Premium
The Fly
Nuvation Bio prices upsized offering of $250M of convertible senior notes
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100